JNNP: predictors of short-term impulsivity and compulsive behavior in patients with Parkinson's disease after receiving hypothalamic stimulation

The subthalamic nucleus (STN) deep brain stimulation (DBS) is a mature treatment method for patients with advanced Parkinson's disease (PD), which can improve the quality of life, sports and non-motor symptoms (NMS)

Specifically, STN-DBS can affect neuropsychiatric symptoms such as depression, anxiety, autism, impulsivity and obsessive-compulsiveness

According to reports, one of the main risk factors for ICB in PD is dopamine replacement therapy, especially dopamine agonists (DA), which may be related to the overstimulation of the mesenchymal dopaminergic system

Since STN-DBS usually leads to a significant reduction of dopaminergic drugs, that is, a reduction in the levodopa equivalent daily dose (LEDD), the improvement of postoperative ICB has been observed

Clinical scales include PD impulse-compulsive disorder questionnaire-score (QUIP-RS), PD questionnaire, non-motor symptom scale (NMSS), unified PD score scale, and levodopa equivalent daily dose total table (LEDD) -total) and dopamine agonists (LEDD-DA)

They enrolled 55 patients with ages of 61.

However, they observed considerable individual differences in clinically relevant QUIP-RS results, because 27.

In post-hoc analysis, higher baseline QUIP-RS and lower baseline LEDD-DA were associated with greater QUIP-RS improvement

The core conclusion of this study is that patients with higher preoperative ICB severity and lower preoperative DA doses have better ICB results, while patients with more severe baseline attention/memory impairment have worse results